RedHill Biopharma (NASDAQ: RDHL)
RedHill Biopharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
RedHill Biopharma Company Info
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
News & Analysis
Why RedHill Biopharma Blasted 12% Higher Today
The company's Opaganib might have a promising future, after all.
Why RedHill Biopharma Stock Is Getting Crushed Today
A clinical failure is sending shareholders to the exits this morning.
Why RedHill Biopharma Stock Jumped on Tuesday
An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated.
Why RedHill Biopharma Stock Is Tanking Today
The drugmaker more than doubled the size of its planned public stock offering.
Why RedHill Biopharma Is Trouncing the Market Today
The company's opaganib shows promise in the fight against the SARS-CoV-2 coronavirus following the completion of a compassionate-use program.
Here's Why RedHill Biopharma Jumped on Monday
The FDA just gave the company's latest treatment the green light.
3 Biotech Stocks That Could Double Your Money
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
Why Redhill Biopharma Ltd. Stock Is Soaring Today
Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.